Meet the Biotech successfully using Bacteria for Immuno-Oncology

20/06/2016 - 4 minutes

Yes, the title may have surprised you, but it’s true. Vaximm is one of the few biotechs worldwide using bacteria to activate the immune system against cancer. I was really surprised about how elegant the technology is when I had a chat with the Executive Chairman Klaus Breiner at BioEquity in Copenhagen.

klaus_breiner_vaximm

Vaximm is based in Basel (Switzerland) and Mannheim (Germany) and was founded in late 2008. The entire platform of the company is based on using an engineered version of commonly-used vaccination bacteria (Ty21a) to present cancer-fighting antigens.

How does it really work? Here’s a diagram from the company:

The engineered bacteria are given orally to the patients. They go to the small intestine’s lymph nodes to infect mostly macrophages, which will then express the specific antigen and after self-destruction are processed by the immune system activating T-cells against that antigen. “Our first-in-class approach is really unique” commented Breiner.

Developing such a platform and novel mechanism of action is definitely not cheap”,

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT Do you want to remove this advert? Become a member!
ADVERTISEMENT Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member